Janux Therapeutics (JANX) Projected to Post Earnings on Friday

Janux Therapeutics (NASDAQ:JANX) is expected to be announcing its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $31.81 on Thursday. Janux Therapeutics has a fifty-two week low of $28.92 and a fifty-two week high of $71.71. The business’s 50 day moving average price is $39.91 and its 200-day moving average price is $47.17. The company has a market cap of $1.88 billion, a P/E ratio of -27.19 and a beta of 3.23.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JANX. BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Stifel Nicolaus lifted their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. Finally, Leerink Partners upped their price objective on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $88.00.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the transaction, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 50,002 shares of company stock valued at $2,684,703. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.